Mark Bonyhadi

Mark Bonyhadi, Ph.D., joined Qiming US in 2018 following a 30+-year career focused on the development of commercially viable approaches for bringing cell therapies, gene-modified cell therapies, and regenerative medicine from the bench to the clinic and into commercial use.
Most recently, Mark held various senior leadership positions in research, process research sciences, and academic affairs at Juno Therapeutics (acquired by Celgene, which was later acquired by BMS).
Previously, Mark was Director of Global Business Development for Cell Therapy at Invitrogen (acquired by Thermo-Fisher).
Mark was responsible for identifying and implementing business opportunities aligned with the cellular medicine portfolio, including leading the launch of the Cell Therapy Systems (CTS™) product line and working with academia and industry to accelerate the development of novel cell and/or gene-based therapies.
Prior to that, Mark served as Director and later Vice President of Research at Xycte Therapies in Seattle, WA, after becoming Senior Scientist at SyStemix, a Palo Alto-based collaborative effort with Sandoz, which later merged with Ciba Geigy to become Novartis.
His work there focused on T cell aspects related to their HIV-1 hematopoietic stem cell gene-therapy approach for treating HIV-1 infections.
Mark completed his postdoctoral training at SyStemix with Dr. Mike McCune and Dr. Hideto Kaneshima studying HIV pathogenesis in the SCID-hu mouse model.
He is a former Chair of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (ASGCT).
He is the inventor on 11 patents and an author on 40 publications.
Mark currently serves as a scientific advisory board member for Akron Biotech.
Mark received a B.A.
from Reed College, Portland, OR, and a Ph.D.
from the University of California Berkeley, where he studied T cell immunology in the lab of Nobel laureate, James P.
Allison.